CANADIAN ADDENDUM TO THE CLINICAL TRIAL COLLABORATION AGREEMENT BETWEEN MEDTRONIC AND ARCATrial Collaboration Agreement • March 19th, 2015 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
This addendum (“Addendum”) is to the Clinical Trial Collaboration Agreement (the “Collaboration Agreement”) made and entered into as of April 18, 2013 between ARCA biopharma, Inc., a Delaware corporation (hereinafter “ARCA”) and Medtronic, Inc., a Minnesota corporation (hereinafter “Medtronic”), as amended by the Second Amendment to the Collaboration Agreement entered as of August 28, 2014. This Addendum is for the purpose of supply and distribution of Medtronic devices and CareLink services within Canada under the Collaboration Agreement.
AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • February 20th, 2020 • Compugen LTD • Biological products, (no disgnostic substances) • New York
THIS AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT (this “Amendment”) is effective as of February 14, 2020 (“Amendment Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • May 1st, 2017 • Exelixis, Inc. • Services-commercial physical & biological research • New York
This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of February 24, 2017 (the “Effective Date”) by and between Exelixis, Inc., a Delaware corporation, located at 210 East Grand Avenue, South San Francisco, CA 94080 (“Exelixis”) and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Exelixis and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
Amendment No. 3 to Master Clinical Trial Collaboration AgreementTrial Collaboration Agreement • November 12th, 2021 • Compugen LTD • Biological products, (no disgnostic substances)
This Amendment No. 3 to Master Clinical Trial Collaboration Agreement (this “Amendment No. 3”) is effective as of November 10, 2021 (“Amendment No. 3 Effective Date”) by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).
MASTER CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • March 29th, 2021 • Checkmate Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS MASTER CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of December 7, 2020 (the “Effective Date”) by and between Checkmate Pharmaceuticals, Inc., a Delaware corporation headquartered at 245 Main Street, Cambridge, MA 02142 (“Checkmate”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, New York. 10016 (“BMS”). Checkmate and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties”.
FIRST AMENDMENT to CLINICAL TRIAL COLLABORATION AGREEMENT between Idenix Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc.,Trial Collaboration Agreement • August 7th, 2013 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations
This first Amendment (the “First Amendment”) to the Clinical Trial Collaboration Agreement (as defined below) shall be effective as of the last of the last signature affixed hereto (“First Amendment Effective Date”), and is entered into by and between Janssen Pharmaceuticals, Inc., having an address at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560, USA (hereinafter referred to as “Janssen”) and Idenix Pharmaceuticals, Inc., a Delaware corporation with a place of business at 60 Hampshire Street, Cambridge, MA 02139 (“Idenix”). Idenix and Janssen may be referred to herein individually as a “Party,” or collectively as the “Parties.”
MASTER CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • November 7th, 2018 • Compugen LTD • Biological products, (no disgnostic substances) • New York
The Parties desire to agree on the following terms in order to develop innovative medicines as promptly as reasonably practicable, to avoid intellectual property and other conflicts with Third Parties in related subject matter transactions, and to better ensure that each Party focuses its efforts on the development of an appropriate Combined Therapy Clinical Trial and that the agreed-upon Combined Therapy Clinical Trial proceed in an effective, cost-efficient and timely manner:
CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • April 22nd, 2013 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
This Clinical Trial Collaboration Agreement (this “Agreement”) is made and entered into as of April 18, 2013 (the “Effective Date”) between ARCA biopharma, Inc., a Delaware corporation (hereinafter “ARCA”), and Medtronic, Inc., a Delaware corporation (hereinafter “Medtronic”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • February 25th, 2013 • Idenix Pharmaceuticals Inc • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of the date of the last signature affixed hereto (the “Effective Date”) by and between Idenix Pharmaceuticals, Inc., a Delaware corporation with a place of business at 60 Hampshire Street, Cambridge, MA 02139 (“Idenix”); and Janssen Pharmaceuticals, Inc., a Pennsylvania corporation with a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (“Janssen”). Idenix and Janssen may be referred to herein individually as a “Party,” or collectively as the “Parties.”
SECOND AMENDMENT TO CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • November 12th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
This Second Amendment to Clinical Trial Collaboration Agreement (this “Amendment”) is made and entered into as of August 28, 2014 (the “Amendment Effective Date”) and amends the Clinical Trial Collaboration Agreement dated April 18, 2013, as amended effective June 15, 2014 (“Agreement”) between ARCA biopharma, Inc., a Delaware corporation (hereinafter “ARCA”), and Medtronic, Inc., a Delaware corporation (hereinafter “Medtronic”) (collectively, the “Parties”).
FIRST AMENDMENT TO CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • August 13th, 2014 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
This First Amendment to Clinical Trial Collaboration Agreement (this “Amendment”) is made and entered into as of June 15, 2014 (the “Amendment Effective Date”) and amends the Clinical Trial Collaboration Agreement dated April 18, 2013 (“Agreement”) between ARCA biopharma, Inc., a Delaware corporation (hereinafter “ARCA”), and Medtronic, Inc., a Delaware corporation (hereinafter “Medtronic”) (collectively, the “Parties”).
SUPPLEMENT TO THE CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • May 1st, 2017 • Exelixis, Inc. • Services-commercial physical & biological research • New York
This SUPPLEMENT TO THE CLINICAL TRIAL COLLABORATION AGREEMENT (the “Supplement”) is made and entered into effective as of February 24, 2017 (the “Effective Date”) by and among Exelixis, Inc., a Delaware corporation, located at 210 East Grand Avenue, South San Francisco, CA 94080 (“Exelixis”), Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”) and Ipsen Pharma SAS, a French Corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (“Ipsen”). The terms in this Supplement with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth herein, or if not defined herein, as set forth in the Agreement (as defined below).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]. FIRST...Trial Collaboration Agreement • March 23rd, 2023 • BioAtla, Inc. • Biological products, (no disgnostic substances) • New York
This First Amendment to the Master Clinical Trial Collaboration Agreement (this “First Amendment”) is entered into on October 14, 2022 (“the First Amendment Effective Date”) by and between Bristol-Myers Squibb Company with offices located at Route 206 and Province Line Road, Princeton, NJ 08543-4000 (“BMS”) and BioAtla, Inc., headquartered at 11085 Torreyana Road, San Diego, California 92121 (the “Company”). Each of BMS and the Company are individually referred to herein as a “Party” and collectively as the “Parties”.
